The Role of Trans-spinal Direct Current Stimulation (tsDCS) in Treating Patients With Hand Spasticity After Stroke
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03080454 |
Recruitment Status :
Completed
First Posted : March 15, 2017
Results First Posted : September 13, 2019
Last Update Posted : April 5, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Stroke Cerebrovascular Accident (CVA) Hemiparesis Spasticity as Sequela of Stroke Muscle Spasticity Upper Extremity Paralysis | Device: sham Doublestim Device: anodal Doublestim | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 26 participants |
Allocation: | Non-Randomized |
Intervention Model: | Crossover Assignment |
Intervention Model Description: | All participants received both stimulation conditions (sham Doublestim and anodal Doublestim), separated by a 1-week washout period. |
Masking: | Single (Participant) |
Masking Description: | The sham stimulation condition preceded the anodal stimulation condition for all participants, and subjects were told they would receive both conditions, but were blinded to order of assignment. |
Primary Purpose: | Treatment |
Official Title: | The Effect of Treatment With the PathMaker Myoregulator Neuromodulation System Incorporating Trans-spinal Direct Current Stimulation (tsDCS) in Patients With Severe Hand Spasticity After Stroke |
Study Start Date : | September 2016 |
Actual Primary Completion Date : | March 2018 |
Actual Study Completion Date : | March 2018 |
Arm | Intervention/treatment |
---|---|
Placebo Comparator: Sham Doublestim
Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). For all participants, the sham condition preceded the anodal Doublestim condition.
|
Device: sham Doublestim
PathMaker MyoRegulator device
Other Name: sham trans-spinal direct current stimulation + peripheral direct current stimulation (tsDCS + pDCS) |
Active Comparator: Anodal Doublestim
Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). For all participants, the sham condition preceded the anodal Doublestim condition.
|
Device: anodal Doublestim
PathMaker MyoRegulator device
Other Name: anodal trans-spinal direct current stimulation + peripheral direct current stimulation (tsDCS + pDCS) |
- Mean Percent Change From Baseline in Area Under the Curve for Objectively Measured Spastic Catch Response of the Wrist Flexors at Fast Speed [ Time Frame: baseline, final session at day 5, 1 week FU ]Subjects' wrists were passively extended at fast speed by a stepper motor to induce a spastic catch response, and its resistance torque was calculated in Newton meters (Nm). Mean percent change from baseline in the area under the curve for the resistance torque were compared across two timepoints (final session at day 5 and 1 week follow-up) in two conditions (sham vs. anodal Doublestim)
- Mean Modified Tardieu Scale (MTS) Score [ Time Frame: baseline, final session at day 5, 1 week FU ]The Modified Tardieu Scale (MTS) quantifies muscle spasticity for each joint at slow and fast velocities on a 0-5 point scale. MTS scores at fast velocity were summed across 11 joints of the upper extremity (for a total of 0-55 points), with lower scores indicating improved spasticity. Mean summed MTS scores (out of 55 total points) were compared across two timepoints (final session at day 5 and 1 week FU) in two conditions (sham vs. anodal Doublestim).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- First single focal unilateral hemisphere lesion with diagnosis verified by brain imaging (MRI or CT scans) that occurred at least 6 months prior
- Cognitive function sufficient to understand the experiments and follow instructions
- A Modified Ashworth Scale score between 1-3 points for wrist flexor and extensor muscles
- A minimum of 15 degrees wrist passive range of motion (ROM) for wrist flexion and extension from wrist neutral position
Exclusion Criteria:
- Focal brainstem or thalamic infarcts
- Prior surgical treatments for spasticity of the upper limb
- Ongoing use of central nervous system (CNS)-active medications
- Ongoing use of psychoactive medications, such as stimulants, antidepressants, and anti-psychotic medications
- Botox or phenol alcohol treatment within 12 weeks of enrollment
- Pregnancy in women, as determined by self-report
- History of spinal cord injury or weakness
- Chronic pain
- Peripheral neuropathy including insulin dependent diabetes as determined by case history
-
Presence of additional potential tsDCS risk factors:
- Damaged skin at the site of stimulation (i.e., skin with ingrown hairs, acne, razor nicks, wounds that have not healed recent scar tissue, broken skin, etc.)
- Presence of an electrically, magnetically or mechanically activated implant (including cardiac pacemaker), an intracerebral vascular clip, or any other electrically sensitive support system
- Highly conductive metal in any part of the body, including metal injury to the eye (jewelry must be removed during stimulation)
- Past history of seizures or unexplained spells of loss of consciousness during the previous 36 months

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03080454
United States, New York | |
Feinstein Institute for Medical Research | |
Manhasset, New York, United States, 11030 |
Documents provided by Bruce Volpe, Northwell Health:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Bruce Volpe, Principal Investigator, Northwell Health |
ClinicalTrials.gov Identifier: | NCT03080454 |
Other Study ID Numbers: |
15-110 |
First Posted: | March 15, 2017 Key Record Dates |
Results First Posted: | September 13, 2019 |
Last Update Posted: | April 5, 2021 |
Last Verified: | August 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
stroke CVA Spasticity hemiparesis |
rehabilitation trans-spinal direct current stimulation (tsDCS) non-invasive stimulation |
Muscle Spasticity Stroke Paralysis Paresis Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Vascular Diseases Cardiovascular Diseases Muscular Diseases Musculoskeletal Diseases Muscle Hypertonia Neuromuscular Manifestations Neurologic Manifestations |